SCHEMBL2230451

SCHEMBL2230451

O=C(OCc1cscn1)N1CCC(CCOc2ccc(C3CCCC3)cc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
CHRM4 P08173 1/20 0.43
GPR119 Q8TDV5 8/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
TEAD1 P28347 1/20 0.40
TEAD3 Q99594 1/20 0.40
HRH3 Q9Y5N1 2/20 0.39
KCNH2 Q12809 1/20 0.39
LTA4H P09960 1/20 0.38
ALOX5 P09917 1/20 0.38
CTSS P25774 1/20 0.38
FAAH O00519 1/20 0.37
GRIN2B Q13224 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2229112 0.87 GRM5 (0.43) CHRM4GPR119MMP2MMP9TEAD1
SCHEMBL2228850 0.87 GRIN2B (0.46) CHRM4GPR119MMP2MMP9TEAD1
SCHEMBL2365458 0.86 LIPE (0.43) GPR119MMP2MMP9TEAD1TEAD3
SCHEMBL2231117 0.86 TEAD1 (0.47) CHRM4GPR119MMP2MMP9TEAD1
SCHEMBL2226384 0.86 HRH3 (0.43) CHRM4GPR119MMP2MMP9TEAD1
SCHEMBL2228891 0.86 TEAD1 (0.50) CHRM4GPR119MMP2MMP9TEAD1
SCHEMBL2363762 0.85 GPR119 (0.47) GPR119MMP2MMP9TEAD1TEAD3
SCHEMBL13837204 0.85 GRIN2B (0.43) CHRM4GPR119MMP2MMP9TEAD1
SCHEMBL2230354 0.84 GRIN2B (0.43) GPR119MMP2MMP9TEAD1TEAD3
SCHEMBL2229931 0.84 TEAD1 (0.46) CHRM4MMP2MMP9TEAD1TEAD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US claimed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP claimed
CN-102803258-A Alkyl-heterocyclic carbamate derivatives, their preparation and therapeutic use SANOFI AVENTIS 2012-11-28 CN claimed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US claimed
US-9000010-B2 Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application SANOFI (FR) 2015-04-07 US disclosed
EP-2526100-B1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI SA (FR) 2013-12-04 EP disclosed
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI (FR) 2012-11-22 US disclosed
WO-2011089550-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION SANOFI AVENTIS (FR) 2011-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295909-A1 ALKYL-HETEROCYCLE CARBAMATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION PRMT9, PRMT8, CBR1 CHRM4 120/4885GPR119 242/4885MMP2 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.